EFLM关于2025/0404(COD) IVDR第5.5条修订提案的立场声明
EFLM就欧盟委员会2025/0404(COD)提案中IVDR第5.5条修订发表立场声明,该提案旨在建立更比例化、基于风险的监管框架,减轻行政负担并现代化临床证据要求。EFLM强烈支持采纳修订后的第5.5条,认为其维持安全与性能保障的同时可促进创新诊断及时可及。
要点
- EFLM强烈支持2025/0404(COD)提案对IVDR第5.5条的修订。
- 修订取消等效性论证要求并认可现有实验室质量管理体系。
- 尚需更清晰定义与协调指南以避免各成员国解释分歧。
核心结论
- EFLM强烈支持采纳2025/0404(COD)提案中修订后的IVDR第5.5条。
- 修订后的第5.5条在维持必要安全与性能保障的同时,可促进创新高质量诊断的及时可及。
主要发现
- IVDR实施导致认证瓶颈、产品撤市、诊断短缺和创新延迟,对中小企业和开发自制体外诊断器械的医疗机构影响尤甚。
- 转向IVDR过程中已有数千项诊断检测丢失。
- 第5.5条限制对罕见病、细分适应症及精准肿瘤学和精准凝血等领域的自制体外诊断器械尤为有害。
关键数值与推荐
- 提案引入更比例化、基于风险的监管框架,减轻行政负担,现代化临床证据要求,并增强可预测性和监管能力。
- 关键改进包括取消等效性论证要求、认可现有实验室质量管理体系、在患者安全或公共卫生需要时增加自制器械使用与转移的灵活性,以及将自制豁免扩展至某些临床试验实验室。
- 剩余挑战包括需要更清晰的定义和协调指南,以避免各成员国解释分歧。
临床怎么用
- 修订后的第5.5条可减少不必要的监管障碍,更好反映实验室实践,防止患者伤害并支持创新。
局限性
- 提案仍缺乏更清晰的定义和协调指南,可能导致各成员国解释分歧。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR) was introduced to enhance patient safety and ensure the availability of safe and effective diagnostics across the European Union. However, its implementation has led to substantial unintended consequences, including certification bottlenecks, market withdrawals, diagnostic shortages, and delayed innovation, with disproportionate impact on small and medium enterprises and on healthcare institutions developing in-house in vitro diagnostic devices (IH-IVDs). As a result, thousands of diagnostic tests have been lost during the transition to IVDR. Restrictions imposed by Article 5.5 of the IVDR have proven particularly harmful for IH-IVDs addressing rare diseases, niche indications, and key developments such as precision oncology and precision coagulation, among others. In December 2025, the European Commission published a targeted legislative proposal (2025/0404(COD)) to amend the IVDR. This EFLM position statement critically evaluates the proposed reforms, with a specific focus on the revision of Article 5.5. The proposal introduces a more proportional, risk-based regulatory framework, reduces administrative burden, modernizes clinical evidence requirements, and strengthens predictability and regulatory capacity. Key improvements include removal of the equivalence justification requirement, recognition of existing laboratory quality management systems, increased flexibility in the use and transfer of in-house devices when justified by patient safety or public health, and extension of the in-house exemption to certain clinical trial laboratories. While the proposal represents a significant step forward, remaining challenges include the need for clearer definitions and harmonized guidance to avoid divergent interpretation across Member States. Overall, EFLM strongly supports the adoption of the revised Article 5.5 as proposed in 2025/0404(COD). The reform maintains essential safety and performance safeguards while enabling timely access to innovative, high-quality diagnostics. By reducing unnecessary regulatory barriers and better reflecting laboratory practice, the proposed revision is essential to prevent patient harm, support innovation, and uphold the original objectives of the IVDR in European diagnostic medicine.
引用
- Cobbaert C, Neumaier M, Capoluongo E, et al. EFLM position statement on the proposed 2025/0404(COD) IVDR Amendment of Article 5.5. Clin Chem Lab Med. 2026. PMID: 42089505. doi:10.1515/cclm-2026-0580
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。